0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Influenza NA Inhibitor Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-6W8674
Home | Market Reports | Health| Health Conditions
Global Influenza NA Inhibitor Market Insights Forecast to 2028
BUY CHAPTERS

Global Influenza NA Inhibitor Market Research Report 2025

Code: QYRE-Auto-6W8674
Report
July 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Influenza NA Inhibitor Market

The global market for Influenza NA Inhibitor was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neuraminidase enzymes are glycoside hydrolase enzymes that cleave (cut) the glycosidic linkages of neuraminic acids. The viral neuraminidases are frequently used as antigenic determinants found on the surface of the influenza virus.
North American market for Influenza NA Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Influenza NA Inhibitor is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Influenza NA Inhibitor include Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, ATK Chemical, Chemwill Asia Co.,Ltd., Shionogi Co., NeoPharm, Moksha8 Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Influenza NA Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza NA Inhibitor.
The Influenza NA Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Influenza NA Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Influenza NA Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Influenza NA Inhibitor Market Report

Report Metric Details
Report Name Influenza NA Inhibitor Market
Segment by Type
  • Zanamivir
  • Oseltamivir
  • Peramivir
Segment by Application
  • Influenza A Treatment
  • Influenza B Treatment
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, ATK Chemical, Chemwill Asia Co.,Ltd., Shionogi Co., NeoPharm, Moksha8 Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Influenza NA Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Influenza NA Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Influenza NA Inhibitor Market report?

Ans: The main players in the Influenza NA Inhibitor Market are Green Cross, Roche, GlaxoSmithKline, Henan DaKen Chemical, ATK Chemical, Chemwill Asia Co.,Ltd., Shionogi Co., NeoPharm, Moksha8 Pharma

What are the Application segmentation covered in the Influenza NA Inhibitor Market report?

Ans: The Applications covered in the Influenza NA Inhibitor Market report are Influenza A Treatment, Influenza B Treatment

What are the Type segmentation covered in the Influenza NA Inhibitor Market report?

Ans: The Types covered in the Influenza NA Inhibitor Market report are Zanamivir, Oseltamivir, Peramivir

1 Influenza NA Inhibitor Market Overview
1.1 Product Definition
1.2 Influenza NA Inhibitor by Type
1.2.1 Global Influenza NA Inhibitor Market Value Comparison by Type (2024 VS 2031)
1.2.2 Zanamivir
1.2.3 Oseltamivir
1.2.4 Peramivir
1.3 Influenza NA Inhibitor by Application
1.3.1 Global Influenza NA Inhibitor Market Value by Application (2024 VS 2031)
1.3.2 Influenza A Treatment
1.3.3 Influenza B Treatment
1.4 Global Influenza NA Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Influenza NA Inhibitor Revenue 2020-2031
1.4.2 Global Influenza NA Inhibitor Sales 2020-2031
1.4.3 Global Influenza NA Inhibitor Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Influenza NA Inhibitor Market Competition by Manufacturers
2.1 Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2020-2025)
2.2 Global Influenza NA Inhibitor Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Influenza NA Inhibitor Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Influenza NA Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Influenza NA Inhibitor, Product Type & Application
2.7 Global Key Manufacturers of Influenza NA Inhibitor, Date of Enter into This Industry
2.8 Global Influenza NA Inhibitor Market Competitive Situation and Trends
2.8.1 Global Influenza NA Inhibitor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Influenza NA Inhibitor Players Market Share by Revenue
2.8.3 Global Influenza NA Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Influenza NA Inhibitor Market Scenario by Region
3.1 Global Influenza NA Inhibitor Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Influenza NA Inhibitor Sales by Region: 2020-2031
3.2.1 Global Influenza NA Inhibitor Sales by Region: 2020-2025
3.2.2 Global Influenza NA Inhibitor Sales by Region: 2026-2031
3.3 Global Influenza NA Inhibitor Revenue by Region: 2020-2031
3.3.1 Global Influenza NA Inhibitor Revenue by Region: 2020-2025
3.3.2 Global Influenza NA Inhibitor Revenue by Region: 2026-2031
3.4 North America Influenza NA Inhibitor Market Facts & Figures by Country
3.4.1 North America Influenza NA Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Influenza NA Inhibitor Sales by Country (2020-2031)
3.4.3 North America Influenza NA Inhibitor Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Influenza NA Inhibitor Market Facts & Figures by Country
3.5.1 Europe Influenza NA Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Influenza NA Inhibitor Sales by Country (2020-2031)
3.5.3 Europe Influenza NA Inhibitor Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Influenza NA Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific Influenza NA Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Influenza NA Inhibitor Sales by Region (2020-2031)
3.6.3 Asia Pacific Influenza NA Inhibitor Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Influenza NA Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Influenza NA Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Influenza NA Inhibitor Sales by Country (2020-2031)
3.7.3 Latin America Influenza NA Inhibitor Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Influenza NA Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Influenza NA Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Influenza NA Inhibitor Sales by Country (2020-2031)
3.8.3 Middle East and Africa Influenza NA Inhibitor Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Influenza NA Inhibitor Sales by Type (2020-2031)
4.1.1 Global Influenza NA Inhibitor Sales by Type (2020-2025)
4.1.2 Global Influenza NA Inhibitor Sales by Type (2026-2031)
4.1.3 Global Influenza NA Inhibitor Sales Market Share by Type (2020-2031)
4.2 Global Influenza NA Inhibitor Revenue by Type (2020-2031)
4.2.1 Global Influenza NA Inhibitor Revenue by Type (2020-2025)
4.2.2 Global Influenza NA Inhibitor Revenue by Type (2026-2031)
4.2.3 Global Influenza NA Inhibitor Revenue Market Share by Type (2020-2031)
4.3 Global Influenza NA Inhibitor Price by Type (2020-2031)
5 Segment by Application
5.1 Global Influenza NA Inhibitor Sales by Application (2020-2031)
5.1.1 Global Influenza NA Inhibitor Sales by Application (2020-2025)
5.1.2 Global Influenza NA Inhibitor Sales by Application (2026-2031)
5.1.3 Global Influenza NA Inhibitor Sales Market Share by Application (2020-2031)
5.2 Global Influenza NA Inhibitor Revenue by Application (2020-2031)
5.2.1 Global Influenza NA Inhibitor Revenue by Application (2020-2025)
5.2.2 Global Influenza NA Inhibitor Revenue by Application (2026-2031)
5.2.3 Global Influenza NA Inhibitor Revenue Market Share by Application (2020-2031)
5.3 Global Influenza NA Inhibitor Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Green Cross
6.1.1 Green Cross Company Information
6.1.2 Green Cross Description and Business Overview
6.1.3 Green Cross Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Green Cross Influenza NA Inhibitor Product Portfolio
6.1.5 Green Cross Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Influenza NA Inhibitor Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Company Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Influenza NA Inhibitor Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Henan DaKen Chemical
6.4.1 Henan DaKen Chemical Company Information
6.4.2 Henan DaKen Chemical Description and Business Overview
6.4.3 Henan DaKen Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Henan DaKen Chemical Influenza NA Inhibitor Product Portfolio
6.4.5 Henan DaKen Chemical Recent Developments/Updates
6.5 ATK Chemical
6.5.1 ATK Chemical Company Information
6.5.2 ATK Chemical Description and Business Overview
6.5.3 ATK Chemical Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.5.4 ATK Chemical Influenza NA Inhibitor Product Portfolio
6.5.5 ATK Chemical Recent Developments/Updates
6.6 Chemwill Asia Co.,Ltd.
6.6.1 Chemwill Asia Co.,Ltd. Company Information
6.6.2 Chemwill Asia Co.,Ltd. Description and Business Overview
6.6.3 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product Portfolio
6.6.5 Chemwill Asia Co.,Ltd. Recent Developments/Updates
6.7 Shionogi Co.
6.7.1 Shionogi Co. Company Information
6.7.2 Shionogi Co. Description and Business Overview
6.7.3 Shionogi Co. Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Shionogi Co. Influenza NA Inhibitor Product Portfolio
6.7.5 Shionogi Co. Recent Developments/Updates
6.8 NeoPharm
6.8.1 NeoPharm Company Information
6.8.2 NeoPharm Description and Business Overview
6.8.3 NeoPharm Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.8.4 NeoPharm Influenza NA Inhibitor Product Portfolio
6.8.5 NeoPharm Recent Developments/Updates
6.9 Moksha8 Pharma
6.9.1 Moksha8 Pharma Company Information
6.9.2 Moksha8 Pharma Description and Business Overview
6.9.3 Moksha8 Pharma Influenza NA Inhibitor Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Moksha8 Pharma Influenza NA Inhibitor Product Portfolio
6.9.5 Moksha8 Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Influenza NA Inhibitor Industry Chain Analysis
7.2 Influenza NA Inhibitor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Influenza NA Inhibitor Production Mode & Process Analysis
7.4 Influenza NA Inhibitor Sales and Marketing
7.4.1 Influenza NA Inhibitor Sales Channels
7.4.2 Influenza NA Inhibitor Distributors
7.5 Influenza NA Inhibitor Customer Analysis
8 Influenza NA Inhibitor Market Dynamics
8.1 Influenza NA Inhibitor Industry Trends
8.2 Influenza NA Inhibitor Market Drivers
8.3 Influenza NA Inhibitor Market Challenges
8.4 Influenza NA Inhibitor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Influenza NA Inhibitor Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Influenza NA Inhibitor Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Influenza NA Inhibitor Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Influenza NA Inhibitor Sales (Tons) of Key Manufacturers (2020-2025)
 Table 5. Global Influenza NA Inhibitor Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Influenza NA Inhibitor Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Influenza NA Inhibitor Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Influenza NA Inhibitor Average Price (US$/Kg) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Influenza NA Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Influenza NA Inhibitor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Influenza NA Inhibitor, Product Type & Application
 Table 12. Global Key Manufacturers of Influenza NA Inhibitor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Influenza NA Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza NA Inhibitor as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Influenza NA Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Influenza NA Inhibitor Sales by Region (2020-2025) & (Tons)
 Table 18. Global Influenza NA Inhibitor Sales Market Share by Region (2020-2025)
 Table 19. Global Influenza NA Inhibitor Sales by Region (2026-2031) & (Tons)
 Table 20. Global Influenza NA Inhibitor Sales Market Share by Region (2026-2031)
 Table 21. Global Influenza NA Inhibitor Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Influenza NA Inhibitor Revenue Market Share by Region (2020-2025)
 Table 23. Global Influenza NA Inhibitor Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Influenza NA Inhibitor Revenue Market Share by Region (2026-2031)
 Table 25. North America Influenza NA Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Influenza NA Inhibitor Sales by Country (2020-2025) & (Tons)
 Table 27. North America Influenza NA Inhibitor Sales by Country (2026-2031) & (Tons)
 Table 28. North America Influenza NA Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Influenza NA Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Influenza NA Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Influenza NA Inhibitor Sales by Country (2020-2025) & (Tons)
 Table 32. Europe Influenza NA Inhibitor Sales by Country (2026-2031) & (Tons)
 Table 33. Europe Influenza NA Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Influenza NA Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Influenza NA Inhibitor Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Influenza NA Inhibitor Sales by Region (2020-2025) & (Tons)
 Table 37. Asia Pacific Influenza NA Inhibitor Sales by Region (2026-2031) & (Tons)
 Table 38. Asia Pacific Influenza NA Inhibitor Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Influenza NA Inhibitor Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Influenza NA Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Influenza NA Inhibitor Sales by Country (2020-2025) & (Tons)
 Table 42. Latin America Influenza NA Inhibitor Sales by Country (2026-2031) & (Tons)
 Table 43. Latin America Influenza NA Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Influenza NA Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Influenza NA Inhibitor Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Influenza NA Inhibitor Sales by Country (2020-2025) & (Tons)
 Table 47. Middle East and Africa Influenza NA Inhibitor Sales by Country (2026-2031) & (Tons)
 Table 48. Middle East and Africa Influenza NA Inhibitor Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Influenza NA Inhibitor Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Influenza NA Inhibitor Sales (Tons) by Type (2020-2025)
 Table 51. Global Influenza NA Inhibitor Sales (Tons) by Type (2026-2031)
 Table 52. Global Influenza NA Inhibitor Sales Market Share by Type (2020-2025)
 Table 53. Global Influenza NA Inhibitor Sales Market Share by Type (2026-2031)
 Table 54. Global Influenza NA Inhibitor Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Influenza NA Inhibitor Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Influenza NA Inhibitor Revenue Market Share by Type (2020-2025)
 Table 57. Global Influenza NA Inhibitor Revenue Market Share by Type (2026-2031)
 Table 58. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2020-2025)
 Table 59. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2026-2031)
 Table 60. Global Influenza NA Inhibitor Sales (Tons) by Application (2020-2025)
 Table 61. Global Influenza NA Inhibitor Sales (Tons) by Application (2026-2031)
 Table 62. Global Influenza NA Inhibitor Sales Market Share by Application (2020-2025)
 Table 63. Global Influenza NA Inhibitor Sales Market Share by Application (2026-2031)
 Table 64. Global Influenza NA Inhibitor Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Influenza NA Inhibitor Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Influenza NA Inhibitor Revenue Market Share by Application (2020-2025)
 Table 67. Global Influenza NA Inhibitor Revenue Market Share by Application (2026-2031)
 Table 68. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2020-2025)
 Table 69. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2026-2031)
 Table 70. Green Cross Company Information
 Table 71. Green Cross Description and Business Overview
 Table 72. Green Cross Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 73. Green Cross Influenza NA Inhibitor Product
 Table 74. Green Cross Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 78. Roche Influenza NA Inhibitor Product
 Table 79. Roche Recent Developments/Updates
 Table 80. GlaxoSmithKline Company Information
 Table 81. GlaxoSmithKline Description and Business Overview
 Table 82. GlaxoSmithKline Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Influenza NA Inhibitor Product
 Table 84. GlaxoSmithKline Recent Developments/Updates
 Table 85. Henan DaKen Chemical Company Information
 Table 86. Henan DaKen Chemical Description and Business Overview
 Table 87. Henan DaKen Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 88. Henan DaKen Chemical Influenza NA Inhibitor Product
 Table 89. Henan DaKen Chemical Recent Developments/Updates
 Table 90. ATK Chemical Company Information
 Table 91. ATK Chemical Description and Business Overview
 Table 92. ATK Chemical Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 93. ATK Chemical Influenza NA Inhibitor Product
 Table 94. ATK Chemical Recent Developments/Updates
 Table 95. Chemwill Asia Co.,Ltd. Company Information
 Table 96. Chemwill Asia Co.,Ltd. Description and Business Overview
 Table 97. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 98. Chemwill Asia Co.,Ltd. Influenza NA Inhibitor Product
 Table 99. Chemwill Asia Co.,Ltd. Recent Developments/Updates
 Table 100. Shionogi Co. Company Information
 Table 101. Shionogi Co. Description and Business Overview
 Table 102. Shionogi Co. Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 103. Shionogi Co. Influenza NA Inhibitor Product
 Table 104. Shionogi Co. Recent Developments/Updates
 Table 105. NeoPharm Company Information
 Table 106. NeoPharm Description and Business Overview
 Table 107. NeoPharm Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 108. NeoPharm Influenza NA Inhibitor Product
 Table 109. NeoPharm Recent Developments/Updates
 Table 110. Moksha8 Pharma Company Information
 Table 111. Moksha8 Pharma Description and Business Overview
 Table 112. Moksha8 Pharma Influenza NA Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2020-2025)
 Table 113. Moksha8 Pharma Influenza NA Inhibitor Product
 Table 114. Moksha8 Pharma Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Influenza NA Inhibitor Distributors List
 Table 118. Influenza NA Inhibitor Customers List
 Table 119. Influenza NA Inhibitor Market Trends
 Table 120. Influenza NA Inhibitor Market Drivers
 Table 121. Influenza NA Inhibitor Market Challenges
 Table 122. Influenza NA Inhibitor Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Influenza NA Inhibitor
 Figure 2. Global Influenza NA Inhibitor Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Influenza NA Inhibitor Market Share by Type: 2024 & 2031
 Figure 4. Zanamivir Product Picture
 Figure 5. Oseltamivir Product Picture
 Figure 6. Peramivir Product Picture
 Figure 7. Global Influenza NA Inhibitor Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Influenza NA Inhibitor Market Share by Application: 2024 & 2031
 Figure 9. Influenza A Treatment
 Figure 10. Influenza B Treatment
 Figure 11. Global Influenza NA Inhibitor Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Influenza NA Inhibitor Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Influenza NA Inhibitor Sales (2020-2031) & (Tons)
 Figure 14. Global Influenza NA Inhibitor Average Price (US$/Kg) & (2020-2031)
 Figure 15. Influenza NA Inhibitor Report Years Considered
 Figure 16. Influenza NA Inhibitor Sales Share by Manufacturers in 2024
 Figure 17. Global Influenza NA Inhibitor Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Influenza NA Inhibitor Players: Market Share by Revenue in Influenza NA Inhibitor in 2024
 Figure 19. Influenza NA Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Influenza NA Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Influenza NA Inhibitor Sales Market Share by Country (2020-2031)
 Figure 22. North America Influenza NA Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Influenza NA Inhibitor Sales Market Share by Country (2020-2031)
 Figure 26. Europe Influenza NA Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Influenza NA Inhibitor Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Influenza NA Inhibitor Revenue Market Share by Region (2020-2031)
 Figure 34. China Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Influenza NA Inhibitor Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Influenza NA Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Influenza NA Inhibitor Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Influenza NA Inhibitor Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Influenza NA Inhibitor Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Influenza NA Inhibitor by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Influenza NA Inhibitor by Type (2020-2031)
 Figure 56. Global Influenza NA Inhibitor Price (US$/Kg) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Influenza NA Inhibitor by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Influenza NA Inhibitor by Application (2020-2031)
 Figure 59. Global Influenza NA Inhibitor Price (US$/Kg) by Application (2020-2031)
 Figure 60. Influenza NA Inhibitor Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

RELATED REPORTS

Global Insulin Coolers Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19Z7671
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Ossicular Prostheses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10V14317
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Defibrillator Accessories Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10O5919
Thu Sep 18 00:00:00 UTC 2025

Add to Cart

Global Septicemia Diagnostic Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4I19963
Thu Sep 18 00:00:00 UTC 2025

Add to Cart